lusvertikimab
ose immunotherapeutics
['ulcerative colitis', 'oseimmuno']
ecco 2023: please come over to our poster presentation! we look forward to discussing data on ose-127 (lusvertikimab) with a novel and differentiated mechanism of action and the only compound targeting il-7r under clinical development in sj gren s syndrome and ulcerative colitis 
focused on the development of innovative immunotherapies for immune activation and regulation in the fields of immune-oncology and auto-immune diseases.